



**Prior Authorization Approval Criteria**  
*Department of Pharmacy Services*

**Generic Name:** eplerenone

**Brand Name:** Inspra

**Medication Class:** Selective aldosterone receptor antagonist

**FDA Approved Uses:** mild to moderate hypertension  
Congestive heart failure post-myocardial infarction

**Usual Dose:** HTN- 50-100mg/day (50mg starting dose)  
CHF- 25-50mg/day (25 mg starting dose)

**Duration of Therapy:** indefinite

**Criteria for Use (HTN):** *(bullet points below are all inclusive unless otherwise noted)*

- Failed/intolerant to therapy with alternative medications including; diuretics, beta blockers, calcium channel blockers, ACE inhibitors, ARBs, spironolactone.
- Documented mild-moderate hypertension
- Document of recent potassium and serum creatinine levels.
  - Serum potassium must be <5.5 mEq/L at initiation.
  - Serum creatinine must be <2.0 mg/dl in males and <1.8 mg/dl in females.
  - Creatinine clearance must be >50 ml/min at initiation.

**Criteria for Use (CHF):** *(bullet points below are all inclusive unless otherwise noted)*

- Clinically documented CHF post MI
- Currently receiving standard care with ACE inhibitors and beta blockers.
- Failed/intolerant to therapy with alternative medications including diuretics, digoxin, ARBs.
- Failed/intolerant to spironolactone.
- Left ventricular ejection fraction (LVEF)  $\leq$  40%.
- Documentation of recent potassium and serum creatinine levels.
  - Serum potassium must be <5.5 mEq/L at initiation.
  - Creatinine clearance must be >30 ml/min at initiation.



**Contraindications:**

- Serum potassium >5.5mEq/L at initiation.
- Creatinine clearance  $\leq$  30ml/min.
- Concomitant use with ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir, or any drug that is a potent CYP3A4 inhibitor.
- Concomitant use of potassium supplements or potassium-sparing diuretics (amiloride, spironolactone, or triamterene).
- For patients with hypertension, Inspra is also contraindicated in the following:(for patients with CHF they should be treated with caution in the following)
  - Type 2 Diabetes and microalbuminuria.
  - Serum creatinine >2.0 mg/dl in males and 1.8 mg/dl in females.
  - Creatinine clearance <50 ml/min.

**Not approved if:**

- Patient has any contraindications to the use of Inspra.

P&T Approval: \_\_\_\_\_ Date: \_\_\_\_\_